NCT04423224

Brief Summary

The study is going to be a single-centre prospective randomized trial. Patients will be randomly allocated to either control group (anesthetist-directed fluid therapy) or goal directed fluid therapy group, in which fluid therapy was guided by stoke volume (SV) algorithm with the use of Nexfin monitor. Primary outcome measures were the time to hospital discharge since surgery and the occurence of complications developed during the postoperative period. Secondary outcomes included the incidence of intraoperative hypotensive episodes (with MAP\<65mmHg) in both groups and the requirement of vasoactive drugs to support blood pressure

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 15, 2018

Completed
2.4 years until next milestone

First Submitted

Initial submission to the registry

June 5, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 9, 2020

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2021

Completed
Last Updated

June 9, 2020

Status Verified

June 1, 2020

Enrollment Period

3.9 years

First QC Date

June 5, 2020

Last Update Submit

June 5, 2020

Conditions

Outcome Measures

Primary Outcomes (2)

  • days of hospitalization after surgery

    days of hospitalization after the operation

    30 days

  • complications

    incidence of complications

    30 days

Secondary Outcomes (2)

  • hypotension

    during surgery

  • use of vasoactive agents

    during surgery

Study Arms (2)

Control group

ACTIVE COMPARATOR

Control group Management of the hemodynamic status in the control group will be performed in the discretion of the attending anesthesiologist, with the aim of keeping mean arterial pressure (MAP) \> 65mmHg. The type and amount of delivered fluids, and vasoactive or inotropic drugs will be recorded.

Other: USUAL CARE - CONTROL

GDFM

ACTIVE COMPARATOR

Goal-directed fluid management group (GDFM). . Baseline SV will be measured after the patients will be turned to left/right position \& before implementation of regional anesthesia. Fluid challenges of 250 ml will be repeated until SV fails to increase by 10%. At this point, preload is considered optimized and SV optimum is defined. SV trigger is defined as SV opt - 10%. N/S 250ml boluses will be administered when SV is below SV trigger. Inotropic drugs will be administered (dobutamine infusion at 0.2-10mcg/kg/min) if CO is below 3.5 L/min and vasopressors (phenylephrine bolus doses of 50-100mcg) if SV and CO are within the target range but MAP is below 65mmHg. Patients will be reassessed during the intraoperative period every 10 minutes . Except from the fluid boluses, all patients will be administered Ringer's lactate solution at an infusion rate of 2ml/kg/h.

Other: GDFM

Interventions

GDFMOTHER

Stroke volume variation fluid management

GDFM

Usual care fluid management

Control group

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients scheduled for hip fracture repair
  • over 60 years of age
  • American Society of Anesthesiologists (ASA) physical status II, III, IV

You may not qualify if:

  • refusal or inability to consent,
  • a plan for general anesthesia
  • expected unreliable measurements of nexfin monitor (e.g. peripheral vascular disease, finger edema).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

2nd Department of Anaesthesiology, Attikon Hospital, 1 Rimini str.

Athens, Attica, 12462, Greece

RECRUITING

2nd Department of Anesthesiology, Attikon Hospital, 1 Rimini str.

Athens, 12462, Greece

RECRUITING

Central Study Contacts

CHRYSANTHI BATISTAKI

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Control group Management of the hemodynamic status in the control group versus a goal directed group based on stroke volume variation protocol (with Nexfin monitor) in patients undergoing hip fracture fixation under spinal anesthesia
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Anaesthesiology

Study Record Dates

First Submitted

June 5, 2020

First Posted

June 9, 2020

Study Start

January 15, 2018

Primary Completion

November 30, 2021

Study Completion

December 30, 2021

Last Updated

June 9, 2020

Record last verified: 2020-06

Locations